Evidence map›Paper›PMID 37593582›Full record

ArticleRSC medicinal chemistry2023

Synthesis and anticancer evaluation of acetylated-lysine conjugated gemcitabine prodrugs.

Mengmeng Wang, Kunyu Qu, Peipei Zhao, Xin Yin, Yiwei Meng, Piet Herdewijn, Chao Liu, Lixin Zhang, Xuekui Xia

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. International journal of molecular sciences · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Mengmeng WangBiology Institute, Qilu University of Technology (Shandong Academy of Sciences) Jinan 250103 China lxzhang@ecust.edu.cn xiaxk@sdas.org.
Kunyu QuBiology Institute, Qilu University of Technology (Shandong Academy of Sciences) Jinan 250103 China lxzhang@ecust.edu.cn xiaxk@sdas.org.
Peipei ZhaoBiology Institute, Qilu University of Technology (Shandong Academy of Sciences) Jinan 250103 China lxzhang@ecust.edu.cn xiaxk@sdas.org.
Xin YinBiology Institute, Qilu University of Technology (Shandong Academy of Sciences) Jinan 250103 China lxzhang@ecust.edu.cn xiaxk@sdas.org.
Yiwei MengBiology Institute, Qilu University of Technology (Shandong Academy of Sciences) Jinan 250103 China lxzhang@ecust.edu.cn xiaxk@sdas.org.
Piet HerdewijnMedicinal Chemistry, Rega Institute for Medical Research, KU Leuven 3000 Leuven Belgium.ORCID https://orcid.org/0000-0003-3589-8503
Chao LiuDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University Jinan 250012 China chaoliu@sdu.edu.cn.ORCID https://orcid.org/0000-0002-7411-7821
Lixin ZhangBiology Institute, Qilu University of Technology (Shandong Academy of Sciences) Jinan 250103 China lxzhang@ecust.edu.cn xiaxk@sdas.org.
Xuekui XiaBiology Institute, Qilu University of Technology (Shandong Academy of Sciences) Jinan 250103 China lxzhang@ecust.edu.cn xiaxk@sdas.org.ORCID https://orcid.org/0000-0001-9673-2828
Qilu University of Technology · CNEast China University of Science and Technology · CNRega Institute for Medical Research · BEShandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gemcitabine is an antimetabolite drug approved for the treatment of various cancers. However, its use is limited due to several issues such as stability, toxicity and drug resistance. Herein, we present the design and synthesis of a series of gemcitabine prodrugs with modifications on the 4-

Identifiers

PMID37593582
PMCPMC10429768
OpenAlexW4383212659

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.